We are a Swiss pharmaceutical wholesaler, specialized in sourcing and delivering pharma products, medical devices and drugs from and to all over the world.
The U.S. Food and Drug Administration has approved Breyanzi (lisocabtagene maraleucel), a cell-based gene therapy to treat adult patients with certain types of large B-cell
The European Commission has granted conditional marketing authorisation for Rozlytrek® (entrectinib) for the treatment of adult and paediatric patients 12 years of age and older with
Elixi International SA
Vicolo Oldelli 12
6830 Chiasso (TI)
Switzerland
Elixi Pharma pte. ltd.
6A Shenton way #04-01
Downtown gallery building
Singapore
